Pharmaceuticals — US PTAB Patent Cases
247 decisions indexed
Page 9 of 9 · 247 total
Formycon AG v.Regeneron Pharmaceuticals, Inc.
Formycon AG has petitioned the PTAB to invalidate 52 claims of Regeneron's anti‑VEGF ophthalmic formulation patent, arguing obviousness over prior‑art formulations and presentations. The petition also challenges any discretionary denial under §§ 314(a) and 325(d).
Formycon AG v.Regeneron Pharmaceuticals, Inc.
The PTAB denied Formycon AG's IPR against Regeneron Pharmaceuticals, Inc., citing substantial overlap with parallel district court proceedings (MDL). The Board found that the interests of system efficiency were best served by denying institution.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s labs and Eye Therapies have jointly filed a motion to keep their settlement agreement confidential and separate from the IPR docket. The request cites statutory authority and seeks limited disclosure.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies have settled their dispute over U.S. Patent No. 11,833,245 and jointly filed a motion to terminate the inter partes review. The Board is asked to end the proceeding under 35 U.S.C. § 317, citing policy and precedent favoring termination after settlement.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories challenges Eye Therapies' patent (11833245) in an IPR, arguing all claims are obvious over prior art including Gil and Norden. The petition asserts that the combination of known elements for treating eye redness is motivated by POSA knowledge, favoring institution under Hatch-Waxman principles.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories successfully secured institution status for an IPR against Eye Therapies, LLC regarding ophthalmic formulations. The Board found a reasonable likelihood of prevailing on obviousness (35 U.S.C. § 103) based on the combination of prior art references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.